OGT CEO Cites 'Exceptional Demand' for Cyto Chips in Decision to Establish US Office | GenomeWeb

Oxford Gene Technology has expanded its effort to serve its North American cytogenetic array customers by establishing an office near New York City and appointing a US-based sales team.

The UK-based clinical genetics company previously served its North American customers from its headquarters outside Oxford, but was moved to establish a direct presence in the US because of "exceptional demand" for its cyto chips, CEO Mike Evans told BioArray News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.